AusPAR: Opdualag

Australian Public Assessment Report

AusPAR

AusPAR: Opdualag [PDF, 1.24 MB]

AusPAR: Opdualag [Word, 1021.7 KB]

Attachment Product information for Opdualag [PDF, 598.61 KB]

Attachment Product information for Opdualag [Word, 187.55 KB]

Device/Product Name

Opdualag

Active ingredients

Nivolumab and Relatlimab

AusPAR Date

22 December 2023

Published

2 January 2024

Submission Number

PM 2021-03689-1-4

Submission Type

New combination

Decision

Approved